Emcure Pharmaceuticals Ltd Share Price
(EMCURE)
₹1008.3▲5.94%
as on 04:01PM, 16 Apr 2025
Emcure Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹941.8Day's Price Range₹1,04052 Week's Low
52 Week's High
₹88952-Week Price Range₹1,580
| Returns % | |
| 1 Month Return | + 2.84 % |
| 3 Month Return | -31.38 % |
| 1 Year Return | -29.97 % |
| Market Stats | |
| Previous Close | ₹951.80 |
| Open | ₹969.90 |
| Volume | 3.57L |
| Upper Circuit | ₹1,046.90 |
| Lower Circuit | ₹856.70 |
| Market Cap | ₹18,035.02Cr |
Emcure Pharmaceuticals Ltd Fundamentals
P/E Ratio
20.98
PEG Ratio
14.08
Market Cap
₹299.10 Cr
P/B Ratio
8.65
EPS
0.74
Dividend Yield
0Sector
Pharmaceuticals
ROE
1.8
Mutual Fund Holdings of Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd Analyst Rating
based on 3 analysts
66.67%
Buy
33.33%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Emcure Pharmaceuticals Ltd. An average target of ₹1535
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Share analysis
Emcure Pharmaceuticals Ltd price forecast by 3 analysts
Upside of61.27%
High
₹1650
Target
₹1535.00
Low
₹1440
Emcure Pharmaceuticals Ltd target price ₹1535, a slight upside of 61.27% compared to current price of ₹1008.3. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Emcure Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:0
Forecast
Actual
Including amortisation and stock based compensations
Emcure Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:0
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Emcure Pharmaceuticals Ltd
Emcure's Namita Thapar Advocates for Diverse Startups - 06 Apr, 2025
Namita Thapar of Emcure Pharmaceuticals emphasized the importance of all types of startups, including those focused on health food, in addressing India's health challenges.Emcure Pharmaceuticals Acquires Manx Healthcare Portfolio - 04 Apr, 2025
Emcure Pharmaceuticals' subsidiary, Tillomed Laboratories, has acquired the pharmaceutical portfolio of Manx Healthcare for £19.7 million. The acquisition aims to diversify offerings and strengthen market presence, despite a 4.77% drop in stock price following the announcement.Emcure Pharma Partners with WiQo for Skin Product - 01 Apr, 2025
Emcure Pharmaceuticals' subsidiary, Emcutix Biopharmaceuticals, has signed an exclusive agreement with Italian company WiQo to import and sell PRX-PLUS, a skin-tightening product, in India. This partnership is expected to enhance Emcure's presence in the growing dermatology market, which is projected to reach $1.8 billion.Bain Capital Plans Stake Sale in Emcure Pharmaceuticals - 31 Mar, 2025
Bain Capital is set to divest its 8.68% stake in Emcure Pharmaceuticals, valued at over ₹1,700 crore, following the end of the lock-in period. Emcure reported a 30.3% increase in net profit for Q3FY25, indicating strong financial performance.Emcure Pharmaceuticals Hits Upper Circuit on New Launch - 20 Mar, 2025
Emcure Pharmaceuticals shares surged 10% to ₹1,025 on the NSE following the announcement of its entry into the daily supplements market under the brand Arth. However, the shares remain 36% below their record high from September 2024.Emcure Pharmaceuticals Launches Daily Supplements Range - 10 Mar, 2025
Emcure Pharmaceuticals enters the daily supplements market with its Arth range, featuring products for women's health. The brand partners with actress Vidya Balan to promote key health issues.
Insights on Emcure Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 15.05% to 15.14% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 2.91% to 3.05% in Dec 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 3.30% to 3.10% in Dec 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 78.08% to 77.94% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, EMCURE stock has moved down by -31.4%
Emcure Pharmaceuticals Ltd Financials
Emcure Pharmaceuticals Ltd Index Inclusions
Emcure Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 77.94% | ||
| Foreign Institutions | 3.05% | 4.85 | |
| Mutual Funds | 3.1% | ||
| Retail Investors | 15.14% | 0.61 | |
| Others | 0.77% | 16.61 |
Emcure Pharmaceuticals Ltd Key Indicators
Emcure Pharmaceuticals Ltd Valuation
Emcure Pharmaceuticals Ltd in the last 5 years
Lowest (27.73x)
April 9, 2025
Today (29.14x)
April 15, 2025
Industry (51.72x)
April 15, 2025
Highest (53.98x)
September 18, 2024
Emcure Pharmaceuticals Ltd Earnings and Dividends
Emcure Pharmaceuticals Ltd Earnings Results
Emcure Pharmaceuticals Ltd’s net profit jumped 35.5% since last year same period to ₹153.72Cr in the Q3 2024-2025. On a quarterly growth basis, Emcure Pharmaceuticals Ltd has generated -21% fall in its net profits since last 3-months.
Read More about Earnings Results
Emcure Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Emcure Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Emcure Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹299.10 Cr | 21.08% | 0.60 | ₹5 Cr | ₹173 Cr | |
| NA | ₹3,585.99 Cr | 160.16% | 0.51 | NA | NA | |
| NA | ₹187.97 Cr | 13.11% | 1.00 | NA | NA | |
| BUY | ₹14,240.60 Cr | -4.49% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| NA | ₹111.54 Cr | -15.07% | 0.50 | NA | NA |
About Emcure Pharmaceuticals Ltd
Revenue: ₹1,962.63Cr as on December 2024 (Q4 24)
Net Profit: ₹156.09Cr as on December 2024 (Q4 24)
Listing date: 10 Jul, 2024
| Organisation | Emcure Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Emcure Pharmaceuticals Ltd
What is Emcure Pharmaceuticals Ltd price today?
Emcure Pharmaceuticals Ltd share price today stands at ₹1008.3, Open: ₹969.9, Previous Close: ₹951.8, High: ₹1040, Low: ₹941.8, 52 Week High: ₹1580, 52 Week Low: ₹889.
How to Buy Emcure Pharmaceuticals Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Emcure Pharmaceuticals Ltd shares
What are today's traded volumes of Emcure Pharmaceuticals Ltd?
Today's traded volume of Emcure Pharmaceuticals Ltd(EMCURE) is 3.57L.
What is today's market capitalisation of Emcure Pharmaceuticals Ltd?
Today's market capitalisation of Emcure Pharmaceuticals Ltd(EMCURE) is ₹18035.02Cr.
What is the 52 Week High and Low Range of Emcure Pharmaceuticals Ltd?
How much percentage Emcure Pharmaceuticals Ltd is down from its 52 Week High?
Emcure Pharmaceuticals Ltd (EMCURE) share price is ₹1008.3. It is down -36.18% from its 52 Week High price of ₹1580
How much percentage Emcure Pharmaceuticals Ltd is up from its 52 Week low?
Emcure Pharmaceuticals Ltd (EMCURE) share price is ₹1008.3. It is up 13.42% from its 52 Week Low price of ₹889